AI基金长盛养老健康混合A（000684）披露2025年二季报，第二季度基金利润265.91万元，加权平均基金份额本期利润0.0437元。报告期内，基金净值增长 率为2.1%，截至二季度末，基金规模为1.27亿元。 该基金属于灵活配置型基金，长期投资于医药医疗股票。截至7月18日，单位净值为2.171元。基金经理是郝征，目前管理4只基金近一年均为正收益。其 中，截至7月18日，长盛医疗量化股票A近一年复权单位净值增长率最高，达29.74%；长盛景气优选混合最低，为13.82%。 基金管理人在二季报中表示，2025 年二季度，医药行业仍然是创新药及产业链为主题。同时三生制药的大额BD落地，使得整体创新药的行情继续得以延 续。本产品主要围绕A股医药产业链进行布局。二季度适当做了一定的分散，减持了部分创新药标的，增加部分高值耗材和中药的配置。但是从产业趋势 看，国内创新药及创新药产业链的产业浪潮仍在进行中，因此对于产业链中业绩增速快或者出海预期确定的标的会选择在调整中继续增加配置。 截至7月18日，长盛养老健康混合A近三个月复权单位净值增长率为13.68%，位于同类可比基金116/138；近半年复权单位净值增长率为 ...

Core Viewpoint - The opening of the Guangzhou Guangjiao Health Industry Park marks a significant step in enhancing the pharmaceutical supply chain and promoting high-quality development in the health industry in Guangzhou and Guangdong Province [1][2]. Group 1: Project Overview - The Guangzhou Guangjiao Health Industry Park, located in Baiyun District, Guangzhou, officially commenced trial operations on July 17, 2025, as a key project for the city [1]. - The park is the first suburban large warehouse base for pharmaceutical supply in Guangzhou and is part of the city's modern commercial circulation system [1][2]. - The total investment in the modern industrial park exceeds 483 million yuan, with construction completed in just 12 months [2]. Group 2: Logistics and Infrastructure - The park features a "three-warehouse" logistics network designed to enhance efficient and safe distribution across urban and rural areas [3]. - It is strategically located near major transport routes, including the North Second Ring Expressway, and is only 20 minutes from Baiyun Airport and the city center [3]. - The logistics center is GSP certified and aims to improve cross-regional and tiered relay delivery services [3]. Group 3: Digital Transformation - The park integrates a digital platform known as "Guangjiao Cloud," which connects various systems for comprehensive visibility and traceability in the pharmaceutical supply chain [4]. - The facility includes a central pharmacy of 80,210 square meters and a cold chain center of 300 square meters [4]. Group 4: Industry Collaboration - On the opening day, ten pharmaceutical companies, including Wanglaoji Pharmaceutical and SF Pharmaceutical, signed cooperation agreements with Guangjiao Logistics [5]. - Wanglaoji Pharmaceutical, a leading company in the health industry, was one of the first to establish operations in the park, indicating strong industry recognition [5]. - The park is actively seeking more pharmaceutical supply chain enterprises to join, aiming to create a distinctive internet-based pharmaceutical circulation cluster in northern Guangzhou [5].

Group 1 - The core viewpoint of the news is that the Shanghai Stock Exchange 300 Pharmaceutical Index has shown significant growth, with a 5.11% increase over the past month, 8.47% over the past three months, and 11.75% year-to-date [1] - The Shanghai Stock Exchange 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the Shanghai and Shenzhen 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base value of 1000.0 points [1] Group 2 - The top ten weighted companies in the Shanghai Stock Exchange 300 Pharmaceutical Index include: Heng Rui Medicine (42.9%), Pian Zai Huang (9.95%), Yunnan Baiyao (8.35%), Kelun Pharmaceutical (6.51%), East China Pharmaceutical (6.41%), Fosun Pharmaceutical (5.58%), New Hecheng (5.56%), Tong Ren Tang (4.09%), Bai Li Tianheng (4.02%), and China Resources Sanjiu (3.51%) [1] - The market share of the index's holdings is 69.65% from the Shanghai Stock Exchange and 30.35% from the Shenzhen Stock Exchange [1] - The composition of the index by industry shows that drug formulations account for 65.43%, traditional Chinese medicine for 29.01%, and raw materials for 5.56% [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to specific calculation and maintenance guidelines [2]

Group 1 - The third China International Supply Chain Promotion Expo (Chain Expo) was held from July 16 to 20 in Beijing, showcasing vibrant cooperation between domestic and foreign enterprises in the health and wellness sector [1] - Starbucks China participated for the third consecutive time, forming a carbon reduction alliance with strategic partners and showcasing its ready-to-drink business for the first time at the expo [2] - L'Oréal, the only foreign beauty company at the expo, highlighted its innovative capabilities in the daily chemical and beauty industry, with 62% of its sales coming from products manufactured in China [2][4] Group 2 - Tsingtao Group presented its complete supply chain system at the expo, celebrating the 50th anniversary of China-Thailand diplomatic relations and emphasizing the importance of China in the global supply chain [3] - The CEO of Tsingtao Group expressed confidence in China's economic prospects and the unique advantages of its supply chain, viewing the expo as a valuable opportunity for international collaboration [3] - Traditional Chinese medicine companies showcased innovative health experiences, with Yiling Pharmaceutical presenting a series of innovative traditional Chinese medicines based on the theory of collateral diseases [4] Group 3 - China Resources Group exhibited its comprehensive health industry ecosystem, focusing on the theme of "Guarding Health Across the Chain, Creating a Better Life" through multimedia interactions and core product displays [5] - Guangdong province, as the guest province, showcased 64 enterprises, including China Resources Group and TCL, highlighting the integration of traditional medicine and modern technology [5] - The health life chain exhibition area demonstrated China's core position in the global health industry chain and the innovative fusion of traditional medicine with modern technology [5]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant allocation in leading healthcare companies [1][3]. - As of July 15, 2025, the latest net value of the fund is 1.7462 yuan, reflecting a growth of 1.28%. The fund's one-month return is 2.18%, six-month return is 18.43%, and year-to-date return is 14.30% [1]. - The fund's top ten stock holdings account for a total of 55.30%, with significant investments in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1]. Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund is managed by Guo Lan and Zhao Lei [1]. - Guo Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]. - Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors, having worked as a researcher and analyst before joining China Europe Fund Management in 2021 [2].

Core Insights - The first aid kit industry is experiencing significant growth due to increased safety awareness and the need for emergency preparedness in various settings such as schools, businesses, and homes [1][11] - The market size of China's first aid kit industry is projected to reach 708 million yuan in 2024, reflecting a year-on-year increase of 4.94% [1][11] - Government policies promoting safety and health have created a favorable environment for the first aid kit industry, making it an essential part of urban and rural development [1][11] Industry Overview - First aid kits are containers that store medical supplies and medications for initial emergency treatment before professional medical help arrives [3] - Different types of first aid kits serve various purposes, including outdoor, disaster, medical, and civilian kits, containing items like oxygen tanks, splints, blood pressure monitors, and dressings [3][7] Market Demand - The demand for first aid kits is increasing due to urbanization and faster-paced lifestyles, leading to a greater need for emergency response to minor injuries and health issues [1][11] - The household first aid kit market is also expanding, with its size projected to grow from 277 million yuan in 2016 to 425 million yuan in 2024, representing a compound annual growth rate of 5.50% [13] Competitive Landscape - The first aid kit industry is becoming more concentrated, with leading companies gaining advantages in market share, technological capabilities, and brand influence [15] - Key players in the industry include Blue Sail Medical, Jiangsu Southern Medicine, and Yunnan Baiyao, among others [15][16][18] Sales Channels - E-commerce platforms are increasingly important for first aid kit sales, benefiting from changing consumer shopping habits and the rapid development of online markets [9] - In 2024, China's e-commerce transaction volume is expected to reach 46.41 trillion yuan, marking a year-on-year increase of 3.90% [9] Future Trends - The market demand for first aid kits is expected to grow due to improvements in the medical emergency system, heightened public health awareness, and the frequency of various emergencies [20] - Future first aid kits may incorporate technologies like IoT and big data for remote monitoring and smart diagnostics, with personalized kits designed for specific demographics such as children and the elderly [20]

Group 1 - The core viewpoint of the articles highlights the performance of the CSI 300 Pharmaceutical Index, which closed at 11,931.35 points, showing a decline of 1.18% over the past month, an increase of 7.25% over the past three months, and a year-to-date increase of 9.53% [1][2] - The CSI 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the CSI 300 Index, reflecting the overall performance of these companies [1] - The top ten weighted companies in the CSI 300 Pharmaceutical Index include: Heng Rui Medicine (43.14%), Pian Zai Huang (10.14%), Yunnan Baiyao (8.49%), Kelun Pharmaceutical (6.31%), East China Pharmaceutical (5.98%), New Harmony (5.69%), Fosun Pharmaceutical (5.53%), Tong Ren Tang (4.16%), Bai Li Tian Heng (3.83%), and China Resources Sanjiu (3.54%) [1] Group 2 - The market share of the CSI 300 Pharmaceutical Index is dominated by the Shanghai Stock Exchange at 69.99%, while the Shenzhen Stock Exchange accounts for 30.01% [2] - In terms of industry composition, the index is primarily made up of drug formulations at 64.78%, traditional Chinese medicine at 29.52%, and raw materials at 5.69% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year, and weights are fixed until the next scheduled adjustment [2]

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

在深圳证监局协同与指导下，深证并购基金联盟、深圳并购重组项目资源库等陆续建立，阳光 普照、种子丰盈、土壤肥沃的并购"生态雨林"正加速形成，持续赋能新质生产力与社会经济高 质量发展。 政策"阳光"普照 并购重组是企业实现基业长青的"关键棋"、突破增长瓶颈的"高速路"，也是经济高质量发展 的"助推器"。新"国九条"发布以来，并购重组政策红利持续释放。 2024年9月，证监会发布"并购六条"，以发挥资本市场在企业并购重组中的主渠道作用，适应 新质生产力的需要和特点，支持上市公司注入优质资产、提升投资价值。 招商证券党委书记、董事长霍达表示，"并购六条"通过允许收购未盈利资产、放宽跨界并购限 制、完善吸并锁定期等规定，向市场传递了积极发展新质生产力、鼓励产业整合的明确信号， 拓宽"链主"企业遴选优质标的的范围，释放了积极有力的政策红利，有利于激发并购重组市场 活力，促进并购交易的市场化发展。 "并购六条"发布后，深圳证监局等有关部门陆续出台并购重组支持政策，健全制度保障。 2024年11月，深圳市委金融办就《深圳市推动并购重组高质量发展的行动方案》公开征求意 见，推出14条创新举措。 丨 来源：中国证券报·中证网 2 ...